An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 501–600 of 1,001
Fabitha, K., Kallingal, A., Maciejewska, N., Arya, C. G., Chandrakanth, M., Thomas, N. M., Li, Y., Gondru, R., Munikumar, M., & Banothu, J. (2024) · New Journal of Chemistry · doi:10.1039/d4nj00824c · Cited by 24
Arya, C. G., Kishore, R., Gupta, P., Gondru, R., Arockiaraj, J., Pasupuleti, M., Chandrakanth, M., Punya, V. P., & Banothu, J. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129881 · Cited by 24
A Microfluidic Platform for the Characterisation of CNS Active Compounds
MacKerron, C., Robertson, G., Zagnoni, M., & Bushell, T. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15950-0 · Cited by 24
The Current Limits in Virtual Screening and Property Prediction
Hutter, M. C. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0303 · Cited by 24
Cryopreservable arrays of paper-based 3D tumor models for high throughput drug screening
Samara, B., Deliorman, M., Sukumar, P., & Qasaimeh, M. A. (2021) · Lab on a Chip · doi:10.1039/d0lc01300e · Cited by 24
Tosca, E. M., Bartolucci, R., Magni, P., & Poggesi, I. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1931114 · Cited by 24
Lou, C., Yang, H., Wang, J., Huang, M., Li, W., Liu, G., Lee, P. W., & Tang, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00297 · Cited by 24
Self-citationCyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors
Thakuri, P. S., Luker, G. D., & Tavana, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.009 · Cited by 24
Wang, W., Wang, N., Wu, Y., Ye, Z., Zhao, L. Y., Chen, X., & Ouyang, D. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3732 · Cited by 23
From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases
Hussain, M. S., Mir, P. A., Kumar, N., Mohi-ud-din, R., Wali, A. F., Mir, R. H., Talath, S., Sridhar, S. B., Shareef, J., Goud, M., et al. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/1070716 · Cited by 23
Al-Amin, R. A., Gallant, C. J., Muthelo, P. M., & Landegren, U. D. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02225 · Cited by 23
Assaggaf, H. M., Hachlafi, N. E., Elbouzidi, A., Taibi, M., Benkhaira, N., Kamari, F. E., Alnasser, S. M., Laaboudi, W., Bouyahya, A., Ardianto, C., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31922 · Cited by 23
Kap, Y. S., Jagessar, S. A., Dunham, J., & Hart, B. A. ‘. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.03.014 · Cited by 23
Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies
Molokanova, E., Mercola, M. A., & Savchenko, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.015 · Cited by 23
Identification of Nontoxic Substructures: A New Strategy to Avoid Potential Toxicity Risk
Yang, H., Sun, L., Li, W., Liu, G., & Tang, Y. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy146 · Cited by 23
How medicinal chemists learned about log P
Martin, Y. C. (2018) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-018-0127-9 · Cited by 23
Saleh‐E‐In, M. M., Roy, A., Al-Mansur, M. A., Hasan, C. M., Rahim, M. M., Sultana, N., Ahmed, S., Islam, M. R., & Staden, J. V. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.11.025 · Cited by 23
Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis
VOGEL, R. M., Erez, A., & Altan-Bonnet, G. Y. (2016) · Nature Communications · doi:10.1038/ncomms12428 · Cited by 23
Generative network complex (GNC) for drug discovery
Grow, C., Gao, K., Nguyen, D. D., & Wei, G. (2019) · Communications in Information and Systems · doi:10.4310/cis.2019.v19.n3.a2 · Cited by 23
Teaching of Biopharmaceutics in a Drug Design Course: Use of GastroPlus as Educational Software
Romero, R. M., Bolger, M. B., Morningstar-Kywi, N., & Haworth, I. S. (2020) · Journal of Chemical Education · doi:10.1021/acs.jchemed.0c00401 · Cited by 23
Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones
Clarelli, F., Palmer, A. C., Singh, B., Storflor, M., Lauksund, S., Cohen, T., Abel, S., & Wiesch, P. A. Z. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008106 · Cited by 23
Suzuki, S., Okada, M., Sanomachi, T., Togashi, K., Seino, S., Satō, A., Yamamoto, M., & Kitanaka, C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015223 · Cited by 23
LaValley, D. J., Miller, P. G., & Shuler, M. L. (2020) · Biotechnology Progress · doi:10.1002/btpr.3105 · Cited by 23
The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhou, Z., Zhu, J., Jiang, M., Sang, L., Hao, K., & He, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050704 · Cited by 23
Polak, S., Romero, K., Berg, A. K., Patel, N. K., Jamei, M., Hermann, D. J., & Hanna, D. L. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9580-2 · Cited by 23
Naritomi, Y., Sanoh, S., & Ohta, S. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00754 · Cited by 23
Parsons, C. G. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.027 · Cited by 22
The OASIS Consortium: integrating multi-omics technologies to transform chemical safety assessment
Rouquié, D., Bender, A., Cheah, J. H., Crute, C., Dalmas, D. A., Ewald, J., Fullerton, A. M., Harrill, J., Kadri, S., Kleinstreuer, N., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf128 · Cited by 22
Roy, N., & Cucullo, L. (2026) · Biosensors · doi:10.3390/bios16030155 · Cited by 22
The influence of calculated physicochemical properties of compounds on their ADMET profiles
Ma, S., McGann, M. R., & Enyedy, I. J. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127825 · Cited by 22
Ohba, Y., Adachi, K., Furukawa, T., Nishimaru, T., Sakurai, K., Masuo, R., Inami, T., Orita, T., Akai, S., Adachi, T., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00433 · Cited by 22
In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives
Afrdi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. Z. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.112943 · Cited by 22
Govindarajan, R., Kumar, N. K., О.П., Ш. О. П. Ш., E., S., Dhatri, B. S., & Pavan Kumar, G. (2025) · Procedia Computer Science · doi:10.1016/j.procs.2025.04.659 · Cited by 22
One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
Chai, C. L. L., & Mátyus, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.167 · Cited by 22
Hansen, S. V. F., Christiansen, E., Urban, C., Hudson, B. D., Stocker, C. J., Due‐Hansen, M. E., Wargent, E. T., Shimpukade, B., Almeida, R., Ejsing, C. S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01962 · Cited by 22
Working towards New Drugs against Parasitic Worms in a Public-Development Partnership
Preston, S., & Gasser, R. B. (2017) · Trends in Parasitology · doi:10.1016/j.pt.2017.07.005 · Cited by 22
Multiscale modelling of drug mechanism and safety
Zhang, J. D., Sach-Peltason, L., Krämer, C., Wang, K., & Ebeling, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.009 · Cited by 22
Gusarov, S., & Stoyanov, S. R. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02836 · Cited by 22
Antioxidant Drug Design: Historical and Recent Developments
Egbujor, M. C., Egu, S. A., Okonkwo, V. I., Jacob, A. D., Egwuatu, P. I., & Amasiatu, I. S. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2020/v32i4131042 · Cited by 22
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization
Selvaggio, G., Leonardelli, L., Lofano, G., Fresnay, S., Parolo, S., Medini, D., Siena, E., & Marchetti, L. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12721 · Cited by 22
Introduction and Historical Overview of Drug Repurposing Opportunities
Pushpakom, S. P. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839163401-00001 · Cited by 22
Strategies to optimize drug half-life in lead candidate identification
Broccatelli, F., Hop, C. E. C. A., & Wright, M. R. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1569625 · Cited by 22
Oja, M., Sild, S., & Maran, U. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00833 · Cited by 22
Engineering Patient-on-a-Chip Models for Personalized Cancer Medicine
Caballero, D., Reis, R. L., & Kundu, S. C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36588-2_4 · Cited by 22
Gupta, N., Choudhary, S. K., Bhagat, N., Muthusamy, K., & Chaturvedi, A. (2021) · Molecules · doi:10.3390/molecules26144147 · Cited by 21
Exploring Low-Toxicity Chemical Space with Deep Learning for Molecular Generation
Yang, Y., Wu, Z., Yao, X., Kang, Y., Hou, T., Hsieh, C., & Liu, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00671 · Cited by 21
Palabindela, R., Bodapati, R., Myadaraveni, P., Gondru, R., & Kasula, M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139067 · Cited by 21
Potential application of artificial intelligence in cancer therapy
Riaz, I. B., Khan, M. A., & Haddad, T. C. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001068 · Cited by 21
Attribute-guided prototype network for few-shot molecular property prediction
Hou, L., Xiang, H., Zeng, X., Cao, D., Zeng, L., & Song, B. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae394 · Cited by 21
Human genetic evidence enriched for side effects of approved drugs
Minikel, E. V., & Nelson, M. R. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011638 · Cited by 21
Li, Z., Yang, J., Gu, W., Cao, G., Fu, X., Sun, X., Zhang, Y., Jin, H. Z., Huang, W., & Qian, H. (2016) · RSC Advances · doi:10.1039/c6ra07356e · Cited by 21
Carbonell, P., Lopez, O., Amberg, A., Pastor, M., & Sanz, F. (2016) · ALTEX · doi:10.14573/altex.1602071 · Cited by 21
Ligandomics: a paradigm shift in biological drug discovery
Li, W., Pang, I.-H., Pacheco, M. T. F., & Tian, H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.013 · Cited by 21
Connecting genetics and gene expression data for target prioritisation and drug repositioning
Ferrero, E., & Agarwal, P. (2018) · BioData Mining · doi:10.1186/s13040-018-0171-y · Cited by 21
Cinnamoyl-Oxaborole Amides: Synthesis and Their in Vitro Biological Activity
Gumbo, M., Beteck, R. M., Mandizvo, T., Seldon, R., Warner, D. F., Hoppe, H. C., Isaacs, M. L., Laming, D., Tam, C. C., Cheng, L. W., et al. (2018) · Molecules · doi:10.3390/molecules23082038 · Cited by 21
Multiparametric Assays for Accelerating Early Drug Discovery
Herholt, A., Galinski, S., Geyer, P. E., Rossner, M. J., & Wehr, M. C. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.005 · Cited by 21
Amirmahani, F., Ebrahimi, N., Molaei, F., Faghihkhorasani, F., Goharrizi, K. J., Mirtaghi, S. M., Boroujeni, M. B., & Hamblin, M. R. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14544 · Cited by 21
An automated approach to identify scientific publications reporting pharmacokinetic parameters
Gonzalez Hernandez, F., Carter, S. J., Iso-Sipilä, J., Goldsmith, P., Almousa, A. A., Gastine, S., Lilaonitkul, W., Kloprogge, F., & Standing, J. F. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16718.1 · Cited by 17
Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value
Gaudillière, J. (2021) · BioSocieties · doi:10.1057/s41292-021-00235-7 · Cited by 21
Novakovsky, G., Sasaki, S., Fornés, O., Omur, M. E., Huang, H., Bayly, C. L., Zhang, D., Lim, N., Cherkasov, A. R., Pavlidis, P., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.01.008 · Cited by 21
Using human experience to identify drug repurposing opportunities: theory and practice
Cavalla, D. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13851 · Cited by 21
Halagali, P., Nayak, D., Seenivasan, R., Manikkath, J., Rathnanand, M., & Tippavajhala, V. K. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010356115241224104018 · Cited by 20
Vemuri, V. D., Lankalapalli, S., & Guntaka, P. R. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103491 · Cited by 20
Czub, N., Pacławski, A., Szlęk, J., & Mendyk, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071415 · Cited by 20
Lou, C., Yang, H., Deng, H., Huang, M., Li, W., Liu, G., Lee, P. W., & Tang, Y. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00707-x · Cited by 20
Advanced tissue engineering for in vitro drug safety testing
Owens, R. M. (2023) · MRS Communications · doi:10.1557/s43579-023-00421-7 · Cited by 20
Hepatoprotective effects of diosmin: a narrative review
Hassanein, E. H. M., Althagafy, H. S., Baraka, M. A., & Amin, H. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03297-z · Cited by 20
Rusyn, I., & Greene, N. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx196 · Cited by 20
Qualifying X-ray and Stimulated Raman Spectromicroscopy for Mapping Cutaneous Drug Penetration
Wanjiku, B., Yamamoto, K., Klossek, A., Schumacher, F., Pischon, H., Mundhenk, L., Rancan, F., Judd, M., Ahmed, M., Zoschke, C., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00519 · Cited by 20
Brown, D. G., Smith, G. F., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01625 · Cited by 20
Batista-Filho, J., Falcão, M. A. P., Maleski, A. L. A., Soares, A. B. S., Balan-Lima, L., Disner, G. R., Lima, C., & Lopes‐Ferreira, M. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.12.004 · Cited by 20
Chemogenomics for drug discovery: clinical molecules from open access chemical probes
Quinlan, R. B. A., & Brennan, P. E. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00016k · Cited by 20
Better science for safer medicines: the human imperative
Archibald, K., Tsaioun, K., Kenna, J. G., & Pound, P. (2018) · Journal of the Royal Society of Medicine · doi:10.1177/0141076818812783 · Cited by 20
Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting
Patel, N. C., Feng, B., Hou, X., West, M. A., Trapa, P. E., Sciabola, S., Verhoest, P. R., Liras, J. L., Maurer, T. S., & Wager, T. T. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00807 · Cited by 19
Kapetas, A. J., Abuhelwa, A. Y., Sorich, M. J., McKinnon, R. A., Rodrigues, A. D., Rowland, A., & Hopkins, A. M. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00632-7 · Cited by 19
Cristiano, G., Bota, P. M., Oliva, B., & Fernández‐Fuentes, N. (2021) · Database · doi:10.1093/database/baab068 · Cited by 19
Hill, J., & Crich, D. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00713 · Cited by 19
El‐Metwally, S. A., Elkady, H., Hagras, M., Husein, D. Z., Ibrahim, I. M., Taghour, M. S., El‐Mahdy, H. A., Ismail, A., Alsfouk, B. A. A., Elkaeed, E. B., et al. (2023) · RSC Advances · doi:10.1039/d3ra03128d · Cited by 19
A new tissue-agnostic microfluidic device to model physiology and disease: the lattice platform
Campo, H., Zha, D., Pattarawat, P., Colina, J. A., Zhang, D., Murphy, A. R., Yoon, J., Russo, A., Rogers, H. B., Lee, H. C., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00378g · Cited by 19
Drug repurposing for glomerular diseases: an underutilized resource
Ng, M. S. Y., Kaur, G., Francis, R. S., Hawley, C. M., & Johnson, D. W. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00864-8 · Cited by 19
Transcriptional response networks for elucidating mechanisms of action of multitargeted agents
Kibble, M., Khan, S. A., Saarinen, N., Iorio, F., Sáez-Rodríguez, J., Mäkelä, S., & Aittokallio, T. A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.03.001 · Cited by 19
Chilton, M., Clennell, B., Edfeldt, F., & Geschwindner, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00208 · Cited by 19
GPCR drug discovery-moving beyond the orthosteric to the allosteric domain
Felder, C. C. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.002 · Cited by 19
Blincoe, W. D., Lin, S., Dreher, S. D., & Sheng, H. (2020) · Tetrahedron · doi:10.1016/j.tet.2020.131434 · Cited by 19
Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets
Zhao, S., Jiang, M., Qing, H., & Ni, J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16187 · Cited by 19
Protein Surface Mimetics: Understanding How Ruthenium Tris(Bipyridines) Interact with Proteins
Hewitt, S. H., Filby, M. H., Hayes, E., Kuhn, L. T., Kalverda, A. P., Webb, M. E., & Wilson, A. J. (2016) · ChemBioChem · doi:10.1002/cbic.201600552 · Cited by 19
Stem cell contributions to neurological disease modeling and personalized medicine
Liang, N., Trujillo, C. A., Negraes, P. D., Muotri, A. R., Lameu, C., & Ulrich, H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.025 · Cited by 19
Nishimura, M., Hayashi, M., Mizutani, Y., Takenaka, K., Imamura, Y., Chayahara, N., Toyoda, M., Kiyota, N., Mukohara, T., Aikawa, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24928 · Cited by 19
Modeling the value of predictive affinity scoring in preclinical drug discovery
Abel, R., Manas, E. S., Friesner, R. A., Farid, R., & Wang, L. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.09.002 · Cited by 19
Yang, M. G., Xiao, Z., Cherney, R. J., Tebben, A. J., Batt, D. G., Brown, G. D., Chen, J., Cvijic, M. E., Dabros, M., Duncia, J. V., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00439 · Cited by 19
Contreras‐Baeza, Y., Ceballo, S., Arce‐Molina, R., Sandoval, P. Y., Alegría, K., Barros, L. F., & Martín, A. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224527 · Cited by 19
Abi‐Gerges, N., Miller, P. E., & Ghetti, A. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666191210142023 · Cited by 19
A Comparative Study of Naive Bayes and k-NN Algorithm for Multi-class Drug Molecule Classification
Mandal, L., & Jana, N. D. (2019) · IEEE India Conference · doi:10.1109/indicon47234.2019.9029095 · Cited by 19
Organotypic Models to Study Human Glioblastoma: Studying the Beast in Its Ecosystem
Pamies, D., Zurich, M., & Härtung, T. (2020) · iScience · doi:10.1016/j.isci.2020.101633 · Cited by 19
Liu, B., Theil, F., Lehmkemper, K., Gessner, D., Li, Y., & van Lishaut, H. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00270 · Cited by 19
Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00311 · Cited by 18
Avram, S., Curpan, R., Halip, L., Bora, A., & Oprea, T. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00826 · Cited by 18
Cordiale, A., Stanco, D., Visone, R., Stadlinger, B., Pagella, P., Rasponi, M., & Mitsiadis, T. A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502080 · Cited by 18
Salame, N., Fooks, K., El-Hachem, N., Bikorimana, J., Mercier, F., & Rafei, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852143 · Cited by 18
Vaghasiya, M. D., Mendapara, J. V., Vaghasiya, S., Rajani, D. P., Ahmad, I., Patel, H., & Kumari, P. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136308 · Cited by 18
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.